REFERENCES
1. Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol 2018;15:694-708.
2. Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 2018;17:48.
3. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 2016;5:288-300.
4. Sukrithan V, Deng L, Barbaro A, Cheng H. Emerging drugs for EGFR-mutated non-small cell lung cancer. Expert Opin Emerg Drugs 2019;24:5-16.
5. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014;11:473-81.
6. Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, et al. Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance. Cancers (Basel) 2019;11.
7. Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, et al. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer 2019;125:892-901.
8. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 2017;49:1693-704.
9. Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015;16:e165-72.
10. Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res 2019;79:689-98.
11. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR Inhibitors. Sci Transl Med 2011;3:75ra26.
12. Jiao Q, Bi L, Ren Y, Song S, Wang Q, et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 2018;17:36.
13. Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H. Liquid-biopsy-based identification of EGFR T790M mutation-mediated resistance to afatinib treatment in patients with advanced EGFR mutation-positive NSCLC, and subsequent response to osimertinib. Target Oncol 2019;14:75-83.
14. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015;21:560-2.
15. Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, et al. Resistance to EGFR inhibitors in non-small cell lung cancer: clinical management and future perspectives. Crit Rev Oncol Hematol 2018;123:149-61.
16. Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res 2018;24:3108-18.
17. Lee JK, Lee J, Kim S, Kim S, Youk J, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol 2017;35:3065-74.
18. Ahn S, Hwang SH, Han J, Choi YL, Lee SH, et al. Transformation to small cell lung cancer of pulmonary adenocarcinoma: clinicopathologic analysis of six cases. J Pathol Transl Med 2016;50:258-63.
19. Dorantes-Heredia R, Ruiz-Morales JM, Cano-García F. Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. Transl Lung Cancer Res 2016;5:401-12.
20. Schoenfeld AJ, Chan JM, Rizvi H, Rekhtman N, Daneshbod Y, et al. Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers. J Clin Oncol 2019;37:9028.
21. Girard N. Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates. Future Oncol 2019;15:2983-97.
22. Tsui DWY, Murtaza M, Wong ASC, Rueda OM, Smith CG, et al. Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. EMBO Mol Med 2018;10.
23. Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, et al. A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics. J Thorac Oncol 2019;14:130-4.
24. Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Comm 2015;6:6377.
26. Marcoux N, Gettinger SN, O’Kane G, Arbour KC, Neal JW, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol 2019;37:278-85.
27. George J, Lim JS, Jang SJ, Cun Y, Ozretić L, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:47-53.
28. Kim Y, Lee B, Shim JH, Lee SH, Park WY, et al. Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC. J Thorac Oncol 2019;14:193-202.
29. Lin CA, Yu SL, Chen HY, Chen HW, Lin SU, et al. EGFR-mutant SCLC exhibits heterogeneous phenotypes and resistance to common antineoplastic drugs. J Thorac Oncol 2019;14:513-26.
30. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011;19:754-64.
31. Park CK, Oh IJ, Kim YC. Is transformed small cell lung cancer (SCLC) different from de novo SCLC? Transl Cancer Res 2019;8:346-9.
32. Shao Y, Zhong DS. Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors. Int J Clin Oncol 2018;23:235-42.
33. Roca E, Gurizzan C, Amoroso V, Vermi W, Ferrari V, et al. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: a systematic review and pooled analysis. Cancer Treat Rev 2017;59:117-22.
34. Sharma S, Kwiat C, Das K, Esposito MJ, Barnaby K, et al. Small cell transformation: an increasingly common mechanism of resistance in EGFR-mutated lung cancer. J Target Ther Cancer 2018.
35. Suda K, Murakami I, Sakai K, Mizuuchi H, Shimizu S, et al. Small cell lung cancer transformation and T790M mutation: complementary roles in acquired resistance to kinase inhibitors in lung cancer. Sci Rep 2015;5:14447.
36. Ham JS, Kim S, Kim HK, Byeon S, Sun JM, et al. Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatment. J Thorac Oncol 2016;11:e1-4.
37. Oh HJ, Park HY, Kim KH, Park CK, Shin HJ, et al. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. J Thorac Dis 2016;8:2530-7.
38. Santoni-Rugiu E. Clinical outcomes provide new insights into transformation to small-cell lung cancer of pulmonary EGFR-mutant adenocarcinoma. Precis Cancer Med 2019;2:5.
39. Farago AF, Piotrowska Z, Sequist LV. Unlocking the mystery of small-cell lung transformations in EGFR mutant adenocarcinoma. J Clin Oncol 2017;35:2987-8.
40. Manca P, Russano M, Pantano F, Tonini G, Santini D. Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib. Oncotarget 2017;8:59986-90.
41. Araki J, Okamoto I, Suto R, Ichikawa Y, Sasaki J. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung Cancer 2005;48:141-4.
42. Shiao TH, Chang YL, Yu CJ, Chang YC, Hsu YC, et al. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol 2011;6:195-8.
43. Lee S, Joo J, Kwak M, Sohn K, Chon S. Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report. Onco Targets Ther 2018;11:3943-7.
44. Hamilton G, Rath B. Role of circulating tumor cell spheroids in drug resistance. Cancer Drug Resist 2019;2:762-72.
45. Terzuoli E, Costanza F, Ciccone V, Ziche M, Morbidelli L, et al. mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines. Prostaglandins Other Lipid Mediat 2019;143:106344.
